drugset / Trial / NCT05331105
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
NaSingle-groupOpen-labelTreatment
Summary
This is a Multi-center, Open-label, Single-arm Phase II Study to Evaluate the Efficacy and Safety of HL-085 in the treatment of Adult Participants with Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas(PN)
Timeline
- Start
- 2021-10-18
- Primary completion
- 2025-10-30
- Completion
- 2028-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tunlametinib | Small molecule | 6 mg | Oral |
| Subject | Tunlametinib | Small molecule | 9 mg | Oral |
| Subject | Tunlametinib | Small molecule | 12 mg | Oral |